Related Experiment Videos
Increased cholesterol levels during paroxetine administration in healthy men
Nathalie Lara1, Glen B Baker, Stephen L Archer
1Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.
The Journal of Clinical Psychiatry
|January 20, 2004
Summary
Selective serotonin reuptake inhibitors like paroxetine may increase low-density lipoprotein cholesterol (LDL-C) levels. This finding is crucial for patients with coronary heart disease (CHD) and those on lipid-lowering medication.
Area of Science:
- Pharmacology
- Cardiology
- Clinical Chemistry
Background:
- Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for patients with coronary heart disease (CHD).
- The impact of SSRIs on plasma lipid profiles in CHD patients remains under-investigated.
- Paroxetine is a frequently used SSRI with potential cardiovascular implications.
Purpose of the Study:
- To systematically evaluate the effects of 8-week paroxetine administration on plasma lipid levels.
- To determine changes in cholesterol and triglyceride concentrations.
- To assess the reversibility of these changes upon paroxetine discontinuation.
Main Methods:
- A study involving 18 healthy male volunteers.
- Blood samples were collected at baseline, after 8 weeks of paroxetine treatment, and after treatment cessation.
- Plasma paroxetine levels were measured to confirm compliance.
Main Results:
- Paroxetine administration led to an 11.5% increase in low-density lipoprotein cholesterol (LDL-C) in compliant participants (16 out of 18).
- Triglyceride levels were not significantly affected.
- The observed increase in LDL-C normalized after paroxetine was discontinued.
Conclusions:
- Paroxetine can elevate LDL-C levels, potentially increasing CHD risk in susceptible individuals.
- The LDL-C increase may necessitate therapeutic intervention in patients with existing CHD.
- Further research is needed to clarify the clinical significance in diverse patient populations.